By Colin Kellaher

Ligand Pharmaceuticals Inc. (LGND) Monday said it signed a worldwide license agreement for its OmniAb antibody discovery platform with Paris drug maker Sanofi S.A. (SAN.FR, SNY).

The San Diego biopharmaceutical company said Sanofi will pay an undisclosed upfront platform access fee, along with development and regulatory milestone payments and potential royalties on sales of marketed products.

Ligand said it has licensed OmniAb to more than 40 companies around the world.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 02, 2019 11:59 ET (16:59 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sanofi Charts.